Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Mack

Showing results (271-280 of 444) with videos related to

Pageof 45
Sort By:
The Oncologist|February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCPhilip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
American Journal of Public Health|June 1, 2006
Unauthorized border crossings and migrant deaths: Arizona, New Mexico, and El Paso, Texas, 2002-2003Sanjeeb Sapkota, Harold W Kohl, Julie Gilchrist, et al.
Investigational New Drugs|February 12, 2010
Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I studyCheryl Ho, Randeep Sangha, Laurel Beckett, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2025
Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymomaJun Ren, Zohreh Amoozgar, Taylor P Uccello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)Philip C Mack, Jieling Miao, Mary W Redman, et al.
Cancer Research|April 3, 2008
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancerOliver Gautschi, Clifford G Tepper, Phillip R Purnell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2013
Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536Edward S Kim, James Moon, Roy S Herbst, et al.
Global Change Biology|April 27, 2018
Cross-scale controls on carbon emissions from boreal forest megafiresXanthe J Walker, Brendan M Rogers, Jennifer L Baltzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2003
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative studyPrimo N Lara, Paul Frankel, Philip C Mack, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327)Primo N Lara, Kari Chansky, Angela M Davies, et al.
Pageof 45

Showing results (271-280 of 444) with videos related to

Sort By:
Pageof 45
The Oncologist|February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCPhilip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
American Journal of Public Health|June 1, 2006
Unauthorized border crossings and migrant deaths: Arizona, New Mexico, and El Paso, Texas, 2002-2003Sanjeeb Sapkota, Harold W Kohl, Julie Gilchrist, et al.
Investigational New Drugs|February 12, 2010
Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I studyCheryl Ho, Randeep Sangha, Laurel Beckett, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2025
Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymomaJun Ren, Zohreh Amoozgar, Taylor P Uccello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)Philip C Mack, Jieling Miao, Mary W Redman, et al.
Cancer Research|April 3, 2008
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancerOliver Gautschi, Clifford G Tepper, Phillip R Purnell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2013
Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536Edward S Kim, James Moon, Roy S Herbst, et al.
Global Change Biology|April 27, 2018
Cross-scale controls on carbon emissions from boreal forest megafiresXanthe J Walker, Brendan M Rogers, Jennifer L Baltzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2003
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative studyPrimo N Lara, Paul Frankel, Philip C Mack, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327)Primo N Lara, Kari Chansky, Angela M Davies, et al.
Pageof 45